
    
      Patients responding criteria for selection and not objecting to participate in this trial
      will address the quality of life questionnaires at baseline and during their standard
      follow-up (1, 6, 12 and 24 months after the end of radiotherapy). The data of toxicity and
      disease-free survival will be collected from data on medical record of the patient.

      The therapeutic support and monitoring are standard.
    
  